SCHEMBL13386253

SCHEMBL13386253

CC(C)(C)OC(=O)N1CCCN(c2cc(F)c3c(c2)Sc2cc(Br)ccc2N3C(=O)OC(C)(C)C)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 7/20 0.41
▸ PDK2 Q15119 1/20 0.38
▸ MAPT P10636 3/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ BCHE P06276 1/20 0.38
▸ ESRRB O95718 1/20 0.37
▸ ESR1 P03372 1/20 0.37
▸ ESRRA P11474 1/20 0.37
▸ ESRRG P62508 1/20 0.37
▸ USP30 Q70CQ3 1/20 0.36
▸ CKS1B P61024 1/20 0.36
▸ SKP1 P63208 1/20 0.36
▸ SKP2 Q13309 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ RBP4 P02753 1/20 0.36
▸ GALR2 O43603 1/20 0.36
▸ GALR1 P47211 1/20 0.36
▸ GPR119 Q8TDV5 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13386281 0.88 PIK3CA (0.41) PDK2MAPTALDH1A1LMNABCHE
SCHEMBL13386122 0.87 BCHE (0.39) BACE1ALDH1A1LMNABCHEUSP30
SCHEMBL12273366 0.82 BCHE (0.49) BACE1MAPTBCHEUSP30MEN1
SCHEMBL13386133 0.80 BCHE (0.40) MAPTALDH1A1LMNABCHEUSP30
SCHEMBL2594780 0.79 PDK2 (0.46) PDK2MAPTALDH1A1LMNABCHE
SCHEMBL13386210 0.79 BCHE (0.42) MAPTALDH1A1LMNABCHEUSP30
SCHEMBL12273405 0.79 BCHE (0.44) BACE1BCHEUSP30MEN1KMT2A
SCHEMBL9933040 0.77 BCHE (0.40) PDK2BCHERBP4GPR119
SCHEMBL29707341 0.75 BACE1 (0.54) BACE1MAPTALDH1A1LMNAUSP30
SCHEMBL7123953 0.75 BACE1 (0.54) BACE1MAPTALDH1A1LMNAUSP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2699241-B1 ANTIVIRAL COMPOUNDS PROSETTA ANTIVIRAL INC (US) 2016-07-27 — — EP disclosed
US-8828986-B2 Antiviral compounds PROSETTA ANTIVIRAL INC. (US) 2014-09-09 — — US disclosed
EP-2699241-A1 ANTIVIRAL COMPOUNDS Prosetta Antiviral Inc. (US) 2014-02-26 — — EP disclosed
WO-2012145567-A1 ANTIVIRAL COMPOUNDS PROSETTA ANTIVIRAL INC. (US) 2012-10-26 — — WO disclosed
US-20120270854-A1 Antiviral Compounds PROSETTA ANTIVIRAL INC. (US) 2012-10-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270854-A1 Antiviral Compounds HAVCR2, MAVS, EIF2AK2 BACE1 1025/4885PDK2 1701/4885MAPT 1569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback